The living-history museum in Fishers is making plans for a larger exhibit that is expected to open in 2029 and better tell ...
There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
Eli Lilly recently updated Q4 revenue guidance, and sales are expected to come in lower than previously anticipated. While this could suggest the company is experiencing sluggish or plateauing ...
It's encouraging to see that Eli Lilly has been growing its earnings per share at 16% a year over the past five years. The company is paying out a lot of its cash as a dividend, but it looks okay ...
In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Unfortunately, the good times didn't last very long. The stock peaked last October and was down by more than 21% when ...
2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (NYSE: LLY). At one point, share prices had gained as much as 65% on the year. However, after a less-than-spectacular earnings ...
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels.
Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates.
and there are a lot of companies trying to get into space.” Cramer pointed out that Eli Lilly’s (NYSE:LLY) investment in GLP-1 drugs is crucial, as these medications are not easy to manufacture.
Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. During that time, it became the world's largest healthcare company, with a market cap that topped $860 billion at one ...